Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.72 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.72 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8299453 | 0.89 | ALDH1A1 (0.75) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| SCHEMBL8887731 | 0.88 | ALDH1A1 (0.73) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| SCHEMBL8889576 | 0.87 | ALDH1A1 (0.72) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| SCHEMBL8887408 | 0.87 | ALDH1A1 (0.72) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| SCHEMBL8299602 | 0.85 | ALDH1A1 (0.69) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| SCHEMBL8300345 | 0.85 | ALDH1A1 (0.69) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| SCHEMBL8888702 | 0.84 | ALDH1A1 (0.68) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL3318 | 0.84 | ALDH1A1 (1.00) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL29614675 | 0.84 | ALDH1A1 (1.00) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL30267890 | 0.84 | ALDH1A1 (1.00) | ALDH1A1LMNAPOLBADORA3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0429987-B1 | 5,11-Dihydro-6H-dipyrido[3,2-b:2',3'-e] [1,4]diazepines and their use in the prevention or treatment of HIV infection | BOEHRINGER INGELHEIM PHARMA (US) | 1999-03-17 | — | — | EP | claimed |
| US-5620974-A | ENZYME INHIBITOR, TREATS ACQUIRED IMMUNE DEFICIENCY SYNDROME(AIDS) | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1997-04-15 | — | — | US | claimed |
| EP-0429987-A2 | 5,11-Dihydro-6H-dipyrido[3,2-b:2',3'-e] [1,4]diazepines and their use in the prevention or treatment of HIV infection | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1991-06-05 | — | — | EP | claimed |
| US-20250221967-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2025-07-10 | — | — | US | disclosed |
| US-20250011333-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2025-01-09 | — | — | US | disclosed |
| CN-119235835-A | Itaconic acid and its derivatives as CDK4/6 inhibitor and antitumor use | 中国药科大学 | 2025-01-03 | — | — | CN | disclosed |
| US-12161687-B2 | Compositions targeting the interaction domain between p27KIP1 and Brk and methods of use thereof to inhibit p27 Y phosphorylation and cdk4 activity | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-12-10 | — | — | US | disclosed |
| WO-2023196727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230053231-A1 | COMPOSITIONS TARGETING THE INTERACTION DOMAIN BETWEEN P27KIP1 AND BRK AND METHODS OF USE THEREOF TO INHIBIT P27 Y PHOSPHORYLATION AND CDK4 ACTIVITY | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-02-16 | — | — | US | disclosed |
| EP-0429987-B1 | 5,11-Dihydro-6H-dipyrido[3,2-b:2',3'-e] [1,4]diazepines and their use in the prevention or treatment of HIV infection | BOEHRINGER INGELHEIM PHARMA (US) | 1999-03-17 | — | — | EP | disclosed |
| US-5620974-A | ENZYME INHIBITOR, TREATS ACQUIRED IMMUNE DEFICIENCY SYNDROME(AIDS) | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1997-04-15 | — | — | US | disclosed |
| US-5366972-A | 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1994-11-22 | — | — | US | disclosed |
| EP-0429987-A2 | 5,11-Dihydro-6H-dipyrido[3,2-b:2',3'-e] [1,4]diazepines and their use in the prevention or treatment of HIV infection | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1991-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250221967-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | RB1, RBBP5, TP53 | ALDH1A1 3489/4885LMNA 2443/4885POLB 1166/4885 |
| US-20250011333-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | ALDH1A1 3081/4885LMNA 2710/4885POLB 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.